跳至主要内容
临床试验/NL-OMON50302
NL-OMON50302已完成不适用

Histological and Microbiological Evaluation of Late Occurring Nodules with Hyaluronic Acid Dermal Fillers - Allergan; 0260/0144; CMO-US-FAS-0486

Allergan (North America)0 个研究点目标入组 3 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
3

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • Have only received HA fillers (no limitation on the brand(s)/product(s) of HA
  • filler used; multiple product use is allowed);
  • Present with an unresolved nodule (inflammatory or non-inflammatory) which
  • was first observed > 4 weeks but < 2 years after the most recent HA filler
  • treatment and is determined to be greater than 3 mm in diameter by palpation;
  • Agree to complete all study required procedures and follow-up; and
  • Provide written informed consent to participate.
  • Have received HA fillers more than once, with the first filler procedure at
  • least two years prior to enrollment;
  • Never developed a nodule;
  • Agree to complete all study required procedures; and
  • Provide written informed consent to participate.

排除标准

  • Have ever received non-HA fillers (e.g. polyacrylamide, calcium
  • hydroxyapatite, poly-L-lactic acid, polymethylmethacrylate, silicone, expanded
  • polytetrafluoroethylene, collagen) including mixes with HA fillers anywhere in
  • Are currently enrolled in a dermal filler clinical trial or previously
  • enrolled in a dermal filler clinical trial with randomized treatment in which
  • the type of dermal filler is unknown (i.e. non-HA filler arm of study);
  • Have a history of keloid or hypertrophic scarring;
  • Are pregnant; and
  • For subjects with a nodule: Have received intralesional intervention for the
  • nodule (e.g. hyaluronidase, corticosteroids, antibiotics, 5-fluorouracil);

研究者

发起方
Allergan (North America)

相似试验